论文部分内容阅读
急性加重是慢性阻塞性肺疾病（ COPD）进展过程中的自然现象，而且在全球范围内的发病率和病死率居高不下。生物标志物（如降钙素原）的检测已经成为诊断及指导 COPD抗生素治疗的一种重要工具。然而，关于降钙素原指导COPD治疗的潜在作用仍在临床研究阶段。该文将通过目前国内外现有的证据证明降钙素原可以用于指导COPD的抗生素治疗。“,”Acute exacerbation of chronic obstructive pulmonary disease ( AECOPD) is a natural event in the course of COPD and is a leading cause of associated morbidity and mortality worldwide .Testing for bio-markers marker,such as procalcitonin(PCT) has emerged as an important tool for the diagnosis and guided antibiotic therapy of patients with COPD .However, questions remain regarding the potential role of PCT to guide therapy in patients with COPD.Here we address the underlying assumptions and the existing evidence supporting a PCT guided approach to antibiotic therapy of COPD in and out of China.